News | May 21, 2026
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The competition received over 42 entries from nursing colleges across Maharashtra
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Subscribe To Our Newsletter & Stay Updated
